Segment Information (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of segment information - net sales and operating earnings

	Three Months Ended March 31
	Net Sales to External Customers				Operating Earnings
(in millions)	2017		2016		2017			2016
Established Pharmaceutical Products	$	950	$	888	$	140		$	148
Nutritional Products	1,642		1,671		351			342
Diagnostic Products	1,158		1,118		284			267
Cardiovascular and Neuromodulation Products	2,103		685		716			247

Total Reportable Segments	5,853		4,362		1,491			1,004
Other	482		523

Net Sales	$	6,335	$	4,885

Corporate functions and benefit plans costs					(190		)	(81		)
Non-reportable segments					46			(2		)
Net interest expense					(204		)	(25		)
Share-based compensation (a)					(171		)	(152		)
Amortization of intangible assets					(522		)	(144		)
Other, net (b)					286			(598		)

Earnings from continuing operations before taxes					$	736		$	2

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net in 2017 includes the gain on the sale of the AMO business, partially offset by inventory step-up amortization, restructuring charges and integration costs associated with the acquisition of St. Jude Medical. Other, net in 2016 includes the $477 million foreign currency loss related to operations in Venezuela and the $43 million impairment of an in-process research and development project related to a non-reportable segment.